Development of high-yield influenza A virus vaccine viruses
about
Tackling a novel lethal virus: a focus on H7N9 vaccine development.An overview of the regulation of influenza vaccines in the United States.A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site.Relationship of influenza virus infection to associated infections in children who present with influenza-like symptoms.Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells.Development of high-yield influenza B virus vaccine virusesWhen gain-of-function research is not "gain-of-function" researchWhat next for gain-of-function research in Europe?Single PA mutation as a high yield determinant of avian influenza vaccines.Effect of the fourth nucleotide at the 3' end of neuraminidase and matrix viral genomic RNA on the pathogenicity of influenza virus A/PR/8/34.Optimized clade 2.3.2.1c H5N1 recombinant-vaccine strains against highly pathogenic avian influenza.Genetic and codon usage bias analyses of polymerase genes of equine influenza virus and its relation to evolution.Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin.Generation of a Genetically Stable High-Fidelity Influenza Vaccine StrainComparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production.Natural Reassortants of Potentially Zoonotic Avian Influenza Viruses H5N1 and H9N2 from Egypt Display Distinct Pathogenic Phenotypes in Experimentally Infected Chickens and Ferrets.A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.Human Clade 2.3.4.4 A/H5N6 Influenza Virus Lacks Mammalian Adaptation Markers and Does Not Transmit via the Airborne Route between Ferrets.Animal Cell Expression Systems.Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure.Novel Platforms for the Development of a Universal Influenza Vaccine.Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A(H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus
P2860
Q30148631-23205BF8-1DCA-40F8-A5C5-B1B0883E2934Q30390639-E1F09BDA-3B0F-4905-89EF-7D43704FC536Q30400507-B3579280-94F7-49A0-A6FE-E179A274E7C3Q36055957-224D3358-43DF-419B-B781-28B6608DB777Q36084675-8A9AE9DB-0910-44D8-97DF-0BF287D0BD01Q36215805-BE86DE2C-AB09-4A19-B397-E94DEC8AAE92Q36410179-1019C116-60A5-4E45-96B3-02E3F448EE05Q36452493-AC2CD321-B3ED-45C0-B27D-032BC4863F30Q37584477-ABFF3AD5-C976-4A83-B2FA-6552CB3B8C75Q40062819-EEFFDEAE-E62C-4144-A153-FBEB151C0FBBQ40062827-873516FE-3A03-4116-B321-29425575C866Q40075092-544FB968-F407-4B0F-8CBD-549208E326EBQ40158695-8954ABFA-81FF-4A6E-AADA-8D850AEFAA01Q40385326-68F5B50F-4D07-4BF6-8013-05856A7351B0Q40766700-B8CA30F8-F77D-449A-A2A6-305759BFF385Q41933463-C1CB4897-EEC1-4892-8EBB-825052E004F2Q45325896-603655B1-5946-47FF-AECF-432672842C32Q47160030-52A5539C-3A10-47F6-8847-448E39AF22D4Q47406183-CC1E9F92-1F35-4E88-ACD7-A989C200C423Q48109162-58D2B98C-B535-44C5-B817-172D0960754EQ52599675-4076C9FA-F9FA-4F06-A9E3-F551FF6AD148Q58794265-17C0B974-390C-4718-9F50-270FF28E1AAE
P2860
Development of high-yield influenza A virus vaccine viruses
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Development of high-yield influenza A virus vaccine viruses
@ast
Development of high-yield influenza A virus vaccine viruses
@en
type
label
Development of high-yield influenza A virus vaccine viruses
@ast
Development of high-yield influenza A virus vaccine viruses
@en
prefLabel
Development of high-yield influenza A virus vaccine viruses
@ast
Development of high-yield influenza A virus vaccine viruses
@en
P2093
P2860
P356
P1476
Development of high-yield influenza A virus vaccine viruses
@en
P2093
Adam Fitch
Catherine A Macken
Chairul A Nidom
Eileen A Maher
Gabriele Neumann
Jihui Ping
Masaki Imai
Tiago J S Lopes
P2860
P2888
P356
10.1038/NCOMMS9148
P407
P577
2015-09-02T00:00:00Z
P5875
P6179
1046886991